Dr. Guojun Bu, Professor Emeritus of the Lu Ka Tung Charitable Foundation and Director of the Life Sciences Department at the Hong Kong University of Science and Technology, recently visited Deep Harbour Cell Valley to explore new pathways for integrating scientific research with industrial applications. Professor Yuanyuan Shi, founder of the valley, along with Chief Medical Officer Dr. Jin David, Chief Scientist Professor Jianxun Wang, Assistant to the Chairman Dr. Yuchen Fu, and Marketing Director Rui Sun, warmly welcomed the distinguished professor. The visit featured in-depth discussions between Dr. Bu and the team on cutting-edge life science research and its industrial translation. Professor Guo Jun Bo is a leading scholar in international neuroscience and biomedical research, specializing in the mechanisms of low-density lipoprotein receptor (LDLR) family in cholesterol metabolism and neurodegenerative diseases such as Alzheimer's disease. He previously served as the Chair of the Department of Neuroscience at Mayo Clinic and Deputy Director of the Alzheimer's Disease Research Center, making him one of the few Chinese scholars to hold a chair position at a world-class institution. Accompanied by Professor Shi Yuanyuan, Professor Bu toured the Smart Exhibition Hall of Deep Harbour Cell Valley, where he gained a comprehensive understanding of the company's technological platforms, research achievements, and clinical applications in gene and cell therapy. He highly commended the company's systematic approach and innovative breakthroughs in industrialization. At the symposium, Professor Shi Yuanyuan outlined the comprehensive development strategy of Deep Harbour Cell Valley, highlighting the company's end-to-end capabilities in viral vectors, cell preparation, GMP production, clinical trials, and technology transfer. The company has partnered with over 80 Grade III-A hospitals nationwide, with extensive product lines covering CAR-T, CAR-NK, natural killer (NK) cells, mesenchymal stem cells (MSCs), and exosomes, addressing diverse clinical needs in oncology, immunological disorders, and anti-aging therapies. Professor Bo Guojun presented the latest advancements in fundamental life science research at the Hong Kong University of Science and Technology (HKUST), highlighting industry-academia collaboration as the key pathway to advancing cell and gene therapies into clinical practice. He noted that HKUST excels in cutting-edge basic research, while Deep Harbour Cell Valley has built strong expertise in technology commercialization. The two institutions share vast potential for collaboration in major disease research like Alzheimer's, with the shared goal of overcoming key technological challenges. This partnership aims to drive high-quality development in the biomedical industry within the Guangdong-Hong Kong-Macao Greater Bay Area, ultimately benefiting global health.